Exosome-Enhanced Microneedling for Hair Loss: What the Science Actually Says
- Epios Cosmetic Clinic
- Jul 1
- 5 min read
Hair loss affects a large proportion of adults, and androgenetic alopecia (pattern hair loss) alone is estimated to affect up to half of the adult population at some stage of life. It is little wonder that regenerative scalp treatments, including microneedling combined with cell-signalling therapies, have become one of the most searched-for topics in cosmetic medicine over the past two years.
At Epios, we are asked regularly whether exosome-enhanced microneedling is a legitimate option for thinning hair, or simply the latest trend. This article sets out what exosomes actually are, what the current clinical evidence shows, how the treatment is delivered safely in Australia, and who is (and isn't) a suitable candidate. As with all higher-risk cosmetic procedures, this is general information only. Suitability can only be determined during an in-person consultation with one of our doctors.
What Are Exosomes?
Exosomes are tiny extracellular vesicles, roughly 30 to 200 nanometres in diameter, naturally released by cells throughout the body. They act as messengers, carrying proteins, lipids and nucleic acids between cells and playing a role in normal processes such as tissue repair, cell communication and inflammation regulation.
In cosmetic and scalp applications, exosomes are typically sourced from cell cultures rather than used as live cells themselves. This distinction matters clinically: because exosomes do not contain the donor cells, they are being investigated for a different risk and regulatory profile than stem cell or tissue-based therapies.
How Is Exosome Therapy Delivered for Hair Loss?
In the Australian regulatory environment, exosome preparations are applied topically. They are not injected. The most common clinical approach pairs a topical exosome solution with microneedling (sometimes called skin needling or collagen induction therapy), a device-based technique that creates controlled, microscopic channels in the scalp.
The rationale for combining the two is mechanical rather than exotic: microneedling temporarily increases the permeability of the scalp, which is thought to improve the penetration of topically applied solutions into the treatment area, while the microneedling process itself is separately associated with improvements in hair density through mechanical stimulation of the follicle and local growth factor release.
Exosome-Enhanced Microneedling for Hair Loss: What Does the Evidence Actually Show?
This is the part that gets skipped in most marketing content, and it is the part that matters most.
Microneedling alone has a reasonably established evidence base for androgenetic alopecia, including a 2026 clinical study combining it with topical minoxidil and finasteride across mild, moderate and severe patient groups, showing measurable improvements in hair density and patient-reported satisfaction over treatment courses of two to four months (Li et al., Journal of Cosmetic Dermatology, 2026).
Exosome microneedling for hair loss is a newer and still-developing field. A prospective open-label study of exosome therapy following microneedling in men with mild to moderate androgenetic alopecia reported improvements in hair regrowth (Wan et al., Aesthetic Plastic Surgery, 2025). A broader systematic review of the available clinical literature, covering randomised controlled trials, prospective single-arm studies and case series across multiple exosome sources and alopecia types, was published in 2025 (Dove Medical Press, Clinical, Cosmetic and Investigational Dermatology); a companion review is also available via PubMed Central (PMC12433634). A separate 2025 scoping review examined exosome delivery methods, including microneedling, in the context of alopecia treatment more broadly (Schaffer et al., Cureus, 2025), and exosome-based approaches have also been reviewed specifically for alopecia areata (PMC12785886). A wider 2025 scoping review of regenerative therapies for androgenetic alopecia, covering ***, photobiomodulation, **** and exosomes together, is available via PubMed Central (PMC12821594).
Findings across this early evidence base have generally trended toward improvements in hair density, hair thickness and patient satisfaction, with a favourable short-term safety profile. However, the reviewers are consistent on one point: study sizes are small, follow-up periods are relatively short, and protocols vary considerably between sources of exosomes, preparation methods and treatment schedules. This means exosome therapy for hair loss should currently be understood as a promising and actively researched adjunct, not as an established, first-line or guaranteed treatment.
We think that distinction is important to say plainly, rather than to gloss over. Good regenerative medicine is built on honest evidence, not hype.
Who Might Be a Candidate?
Because hair loss has multiple underlying causes, ranging from androgenetic alopecia to alopecia areata, telogen effluvium, nutritional deficiency and thyroid or hormonal conditions, a proper diagnosis always precedes any discussion of treatment options. A doctor-led consultation typically includes a review of hair loss pattern and history, relevant bloodwork where indicated, and a discussion of realistic expectations and the current evidence base for each option available.
What to Expect at Your Consultation
Every treatment plan at Epios begins with a consultation with one of our doctors, not a scheduling call. This is where your specific type and stage of hair loss is assessed, your suitability for scalp microneedling and adjunct therapies is discussed, and a personalised plan (which may include established options such as topical or oral therapies, alongside newer regenerative approaches) is developed. We do not make guarantees about outcomes, as individual results vary and depend on the underlying cause and severity of hair loss.
Frequently Asked Questions
Is exosome therapy for hair loss approved in Australia? Exosome products are not currently included on the Australian Register of Therapeutic Goods (ARTG) for hair loss.
Is scalp microneedling painful? Most patients describe mild discomfort rather than pain.
How many sessions are typically needed? Published protocols vary, with courses generally ranging from a handful of sessions over several months. Your doctor will discuss a schedule based on your individual assessment, as there is no universal protocol.
Is this a cure for hair loss? No treatment, regenerative or otherwise, can be described as a cure for hair loss. Outcomes vary by individual, underlying cause and consistency of any ongoing maintenance plan.
How is this different from PRP? Platelet-rich plasma (PRP) is prepared from the patient's own blood. Exosome preparations are typically derived from cell culture sources rather than the patient directly. Both are being researched as regenerative adjuncts for hair loss, and your doctor can discuss which, if either, may be appropriate for you.
Book a Consultation
If you are experiencing hair thinning or loss and want to understand your options, book a consultation with one of our doctors at Epios Cosmetic Clinic, Paddington. We will assess your individual presentation and talk you through an evidence-based plan.
References
Li, G., Geng, J., Liang, J., et al. "Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of Androgenetic Alopecia." Journal of Cosmetic Dermatology, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12883901/
Wan, J., Kim, S.B., Cartier, H., et al. "A Prospective Study of Exosome Therapy for Androgenetic Alopecia." Aesthetic Plastic Surgery, 49, 3151–3156, 2025. https://link.springer.com/article/10.1007/s00266-025-04817-9
"Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources." Clinical, Cosmetic and Investigational Dermatology, Dove Medical Press, 2025. https://www.dovepress.com/exosomes-and-hair-regeneration-a-systematic-review-of-clinical-evidenc-peer-reviewed-fulltext-article-CCID
Same study, PubMed Central copy. https://pmc.ncbi.nlm.nih.gov/articles/PMC12433634/
Schaffer, S., Tehrani, L., Koechle, B., et al. "A Scoping Review of Exosome Delivery Applications in Hair Loss." Cureus, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020662/
"Exosome-Based Therapies for Alopecia Areata: A Systematic Review of Clinical and Experimental Evidence." PubMed Central, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12785886/
"Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes." PubMed Central, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821594/
Therapeutic Goods Administration. "Regulation of Stem Cell Treatments: Information for Practitioners." https://www.tga.gov.au/regulation-stem-cell-treatments-information-practitioners